公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2016 | Four-year entecavir therapy reduces hepatocellular carcinoma, cirrhotic events and mortality in chronic hepatitis B patients | TUNG-HUNG SU ; Hu T.-H.; Chen C.-Y.; Huang Y.-H.; Chuang W.-L.; Lin C.-C.; Wang C.-C.; Su W.-W.; Chen M.-Y.; Peng C.-Y.; Chien R.-N.; Huang Y.-W.; Wang H.-Y.; Lin C.-L.; Yang S.-S.; Chen T.-M.; Mo L.-R.; SHIH-JER HSU ; Tseng K.-C.; Hsieh T.-Y.; Suk F.-M.; Hu C.-T.; Bair M.-J.; Liang C.-C.; Lei Y.-C.; TAI-CHUNG TSENG ; CHI-LING CHEN ; JIA-HORNG KAO ; the C-TEAM study group; the Taiwan Liver Diseases Consortium | Liver International | 165 | 149 | |
2014 | Higher adherence with 3-year entecavir treatment than lamivudine or telbivudine in treatment-naïve Taiwanese patients with chronic hepatitis B | Chien R.-N.; Peng C.-Y.; JIA-HORNG KAO ; Hu T.-H.; Lin C.-C.; Hu C.-T.; Chen C.-Y.; Hsieh T.-Y.; Lin H.-C.; Chuang W.-L. | Journal of Gastroenterology and Hepatology (Australia) | 9 | 8 | |
2016 | Ledipasvir/sofosbuvir fixed-dose combination tablet in Taiwanese patients with chronic genotype 1 hepatitis C virus | Chuang W.-L.; Chien R.-N.; Peng C.-Y.; Chang T.-T.; Lo G.-H.; Sheen I.-S.; Wang H.-Y.; Chen J.-J.; Yang J.C.; Knox S.J.; Gao B.; Garrison K.L.; Mo H.; Pang P.S.; Hsu Y.-C.; Hu T.-H.; Chu C.-J.; JIA-HORNG KAO | Journal of Gastroenterology and Hepatology (Australia) | 24 | 20 | |
2021 | Ledipasvir/Sofosbuvir for 8, 12, or 24 Weeks in Hepatitis C Patients Undergoing Dialysis for End-Stage Renal Disease | Chuang W.-L.; Hu T.-H.; Buggisch P.; Moreno C.; Su W.-W.; Biancone L.; Camargo M.; Hyland R.; Lu S.; Kirby B.J.; Dvory-Sobol H.; Osinusi A.; Gaggar A.; Peng C.-Y.; CHEN-HUA LIU ; Sise M.E.; Mangia A. | The American journal of gastroenterology | 7 | 6 | |
2011 | Long-term effect of interferon plus ribavirin on hepatitis B surface antigen seroclearance in patients dually infected with hepatitis B and C viruses | Yeh M.-L.; Hung C.-H.; Huang J.-F.; CHUN-JEN LIU ; Lee C.-M.; Dai C.-Y.; Wang J.-H.; Lin Z.-Y.; Lu S.-N.; Hu T.-H.; Yu M.-L.; JIA-HORNG KAO ; Chuang W.-L.; PEI-JER CHEN ; DING-SHINN CHEN | PLoS ONE | 19 | 15 | |
2016 | A phase 3b study of sofosbuvir plus ribavirin in Taiwanese patients with chronic genotype 2 hepatitis C virus infection | JIA-HORNG KAO ; Chien R.-N.; Chang T.-T.; Peng C.-Y.; Hu T.-H.; Lo G.-H.; Wang H.-Y.; Chen J.-J.; Yang J.C.; Knox S.J.; Han L.; Mo H.; Mathias A.; Brainard D.M.; Sheen I.-S.; Hsu Y.-C.; Chu C.-J.; Chuang W.-L. | Liver International | 25 | 25 | |
2015 | A polymorphism in interferon L3 Is an independent risk factor for development of hepatocellular carcinoma after treatment of hepatitis c virus infection | Chang K.-C.; Tseng P.-L.; Wu Y.-Y.; Hung H.-C.; Huang C.-M.; Lu S.-N.; Wang J.-H.; Lee C.-M.; Chen C.-H.; Tsai M.-C.; Yen Y.-H.; Lin M.-T.; Wu C.-K.; Huang C.-C.; Chen, Tony Hsiu Hsi ; Hu T.-H. | Clinical Gastroenterology and Hepatology | 49 | 47 | |
2021 | Preoperative ALBI grade predicts the outcomes in non-B non-C HCC patients undergoing primary curative resection | YU-CHIEH TSAI ; Sou F.-M.; Liu Y.-W.; Wu Y.-J.; Yong C.-C.; Chen D.-W.; Huang P.-Y.; Cho W.-R.; Chuang C.-H.; Hsiao C.-C.; Hu T.-H.; Tsai M.-C. | BMC Gastroenterology | 6 | 7 | |
2015 | Reply | Chen, Tony Hsiu Hsi ; Yeh Y.-P.; Lao C.-S.; Hu T.-H.; Yen A.M.-F.; Wu W.Y.-Y. | Hepatology | 0 | 0 | |
2021 | Statin use is associated with a lower risk of recurrence after curative resection in BCLC stage 0-A hepatocellular carcinoma | Yang S.-Y.; Wang C.-C.; Chen K.-D.; Liu Y.-W.; Lin C.-C.; Chuang C.-H.; YU-CHIEH TSAI ; Yao C.-C.; Yen Y.-H.; Hsiao C.-C.; Hu T.-H.; Tsai M.-C. | BMC Cancer | 12 | 11 | |
2019 | Taiwan consensus statement on the management of chronic hepatitis B | Chien R.-N.; JIA-HORNG KAO ; Peng C.-Y.; Chen C.-H.; CHUN-JEN LIU ; Huang Y.-H.; Hu T.-H.; Yang H.-I.; Lu S.-N.; YEN-HSUAN NI ; Chuang W.-L.; Lee C.-M.; Wu J.-C.; PEI-JER CHEN ; Liaw Y.-F. | Journal of the Formosan Medical Association | 50 | 47 |